Adele Caterino-de-Araujo1, Edel Figueiredo Barbosa-Stancioli2, José Boullosa Alonso Neto3, Mayra Gonçalves Aragón4, Bernardo Galvão-Castro5, Ricardo Ishak6, Carolina Rosadas7. 1. Instituto Adolfo Lutz, Centro de Imunologia, Laboratório de Pesquisa em HTLV, São Paulo, SP, Brasil. 2. Universidade Federal de Minas Gerais, Instituto de Ciências Biológicas, Laboratório de Virologia Básica e Aplicada, Belo Horizonte, MG, Brasil. 3. Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de Doenças de Condições Crônicas e Infecções Sexualmente Transmissíveis, Brasília, DF, Brasil. 4. Universidade Federal do Espírito Santo, Programa de Pós-Graduação em Doenças Infecciosas, Vitória, ES, Brasil. 5. Escola Bahiana de Medicina e Saúde Pública, Centro Integrativo e Muldisciplinar de Atendimento ao Portador de HTLV, Salvador, BA, Brasil. 6. Universidade Federal do Pará, Instituto de Ciências Biológicas, Laboratório de Virologia, Belém, PA, Brasil. 7. Imperial College Healthcare NHS Trust, St. Mary's Hospital, National Centre for Human Retrovirology, London, United Kingdom.
Abstract
INTRODUCTION: We present a data analysis and review of recent studies regarding the laboratory diagnosis of human T-lymphotropic virus 1 and 2 (HTLV-1/2) infections in Brazil. METHODS: Target populations, available diagnostic serological assays (screening and complementary tests), molecular assays (in-house), causes of false-positive and false-negative results, and flowcharts were analyzed. RESULTS: A table presents the target populations, two diagnostic flowcharts (depending on laboratory infrastructure and study population), and recent research that may improve how HTLV-1/2 is diagnosed in Brazil. CONCLUSIONS: Our results support the implementation of public policies to reduce HTLV-1/2 transmission and its associated diseases.
INTRODUCTION: We present a data analysis and review of recent studies regarding the laboratory diagnosis of humanT-lymphotropic virus 1 and 2 (HTLV-1/2) infections in Brazil. METHODS: Target populations, available diagnostic serological assays (screening and complementary tests), molecular assays (in-house), causes of false-positive and false-negative results, and flowcharts were analyzed. RESULTS: A table presents the target populations, two diagnostic flowcharts (depending on laboratory infrastructure and study population), and recent research that may improve how HTLV-1/2 is diagnosed in Brazil. CONCLUSIONS: Our results support the implementation of public policies to reduce HTLV-1/2 transmission and its associated diseases.
Authors: Gabriela de Melo Franco; Anderson Santos da Rocha; Laura Jorge Cox; Danielle Soares de Oliveira Daian E Silva; Débora Marques da Silveira E Santos; Marina Lobato Martins; Luis Claudio Romanelli; Ricardo Ishak; Antonio C R Vallinoto; Maria Rosa Q Bomfim; Adele Caterino-de-Araujo; Jordana G A Coelho-Dos-Reis; Flávio Guimarães da Fonseca; Edel Figueiredo Barbosa-Stancioli Journal: Front Public Health Date: 2022-05-23
Authors: Felipe Teixeira Lopes; Renata Santos de Sousa; Jayanne L Carvalho Gomes; Mariana Cayres Vallinoto; Aline Cecy Rocha de Lima; Sandra Souza Lima; Felipe Bonfim Freitas; Rosimar N Martins Feitosa; Andrea Nazaré M Rangel da Silva; Luiz Fernando A Machado; Cintia Y P Aben-Athar; Eduardo Leitão Maia da Silva; Izaura M V Cayres Vallinoto; Antonio Carlos R Vallinoto Journal: Front Public Health Date: 2022-03-28
Authors: Angelica Espinosa Miranda; Carolina Rosadas; Tatiane Assone; Gerson Fernando Mendes Pereira; Antonio Carlos Rosário Vallinoto; Ricardo Ishak Journal: Front Med (Lausanne) Date: 2022-04-07